Treatment(s) already received-Bone marrow transplant Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Bone marrow transplant Posts on Medivizor

Maintenance rituximab plus bortezomib for mantle cell lymphoma

Posted by on Aug 1, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of rituximab (Rituxan) plus bortezomib (Velcade) for patients with mantle cell lymphoma after stem cell transplant. This study concluded that this combination is a safe and effective regimen in these patients. Some background The standard treatment for younger patients with mantle cell...

Read More

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...

Read More

Is there a link between recovery time for healthy white blood cells and infections in children with AML?

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of neutrophil recovery time (NRT – the return of white blood cells after treatment, that fight infection) on infections and relapse (return of disease) in children with acute myeloid leukaemia (AML). The study found that longer NRT was linked with increased risk of severe infections and relapse after...

Read More

Is there a link between recovery time for healthy white blood cells and infections in children with AML?

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of neutrophil recovery time (NRT – the return of white blood cells after treatment, that fight infection) on infections and relapse (return of disease) in children with acute myeloid leukaemia (AML). The study found that longer NRT was linked with increased risk of severe infections and relapse after...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More

Treatment for acute myeloid leukemia patients involving thiotepa and stem cell transplant.

Posted by on Mar 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the use of stem cell transplant with a chemotherapy treatment regime in patients with acute myeloid leukemia. This study concluded that this regime is safe and effective in patients that receive stem cell transplants from a haploidentical (half or partially matched) donor. Some background The use of...

Read More

Risk factors that influence outcomes for acute leukemia patients with relapse after hematopoietic stem cell transplant.

Posted by on Mar 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...

Read More

How safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...

Read More

The prevalence of metabolic syndrome in survivors of childhood acute leukemia

Posted by on Mar 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the prevalence of metabolic syndrome in adult survivors of childhood acute leukemia. This study also aimed to determine the effect of different therapies on the occurrence of metabolic syndrome in these patients. This study concluded that metabolic syndrome is frequent among childhood AL survivors, regardless...

Read More

Antithymocyte globulin before transplantation for patients with acute myeloid leukemia

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to analyze the impact of antithymocyte globulin doses in patients with acute myeloid leukemia in first complete remission undergoing transplantation. This study concluded that an antithymocyte globulin dose less than 6mg/kg is enough to prevent graft versus host disease. Doses higher than this impair disease control and...

Read More